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Nuclear factor kappa-B (NFkB), a redox-sensitive transcription factor regulating a battery of
inflammatory genes, has been indicated to play a role in the development of numerous
pathological states. Activation of NFkB induces gene programs leading to transcription of
factors that promote inflammation, such as leukocyte adhesion molecules, cytokines, and
chemokines, although some few substances with possible anti-inflammatory effects are also
NFkB regulated. The present article reviews basic regulation of NFkB and its activation, cell
biological effects of NFkB activation and the role of NFkB in apoptosis. Evidence involving
NFkB as a key factor in the pathophysiology of ischemia-reperfusion injury and heart failure
is discussed. Although activation of NFkB induces pro-inflammatory genes, it has lately been
indicated that the transcription factor is involved in the signaling of endogenous myocardial
protection evoked by ischemic preconditioning. A possible role of NFkB in the development
of atherosclerosis and unstable coronary syndromes is discussed. Nuclear factor kappa-B may
be a new therapeutic target for myocardial protection. (J Am Coll Cardiol 2001;38:307–14)
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Nuclear factor kappa-B (NFkB) is a redox-sensitive tran-
scription factor regulating a battery of inflammatory genes;
it has been implicated as important for initiation and
progression of pathogenesis in atherosclerosis, inflammatory
bowel disease, autoimmune arthritis, glomerulonephritis,
asthma, lung fibrosis, septic shock, carcinogenesis and
AIDS (1–3). A key role for NFkB is becoming apparent in
the pathophysiology of myocardial ischemia-reperfusion
injury, ischemic preconditioning and unstable angina.
ACTIVATION OF NFkB
Nuclear factor kappa-B can be activated by reactive oxygen
intermediates, hypoxia/anoxia, hyperoxia, cytokines, protein
kinase C activators, mitogen-activated protein kinase
(MAPK) activators, bacterial or viral products, such as
lipopolysaccharide (LPS), dsRNA, or the human T-cell
leukemia virus type 1 Tax protein, and by UV-radiation
(1–7). A schematic presentation of NFkB activation is
shown in Figure 1. NFkB regulates genes involved in both
innate and adaptive immunity, among them pro-
inflammatory cytokines, chemokines, leukocyte adhesion
molecules and inflammatory enzymes (for details see reviews
1–4). The NFkB family consists of the members p50, p52,
p65 (RelA), c-Rel, and RelB, which form various homo-
and heterodimers, where the most common active form is
the p50 or p52/RelA heterodimer. The NFkB dimers in
resting cells reside in the cytoplasm in an inactive form
bound to inhibitory proteins known as IkB. At least six IkB
proteins are involved in controlling the activity of the NFkB
dimer (1–4). Both IkBa and IkBb, the two stimulus-
regulatory proteins of NFkB, have two N-terminal serine
residues that are phosphorylated in response to diverse
stimuli. The phosphorylated IkBs are then ubiquitinated
and proteolytically degraded. This process activates NFkB,
which translocates to the nucleus and binds to promoter or
enhancer regions of specific genes, initiating transcription
(1–4).
A crucial step in the activation of NFkB is the phosphor-
ylation of IkBs by a 700- to 900-kDa multimeric complex,
referred to as the IkB kinase (IKK) complex (8). The IKK
complex consists of two catalytic subunits (IKK1/IKKa and
IKK2/IKKb) (9–11), the NFkB essential modulator alter-
natively referred to as NEMO (12), IKKg (13), IKK-
associated protein (14) or FIP-3 (15). Although not itself a
kinase, NEMO mediates crucial protein-protein interac-
tions, possibly with upstream activators of the kinase com-
plex (12,13). Activation of the IKK complex is mediated via
phosphorylation of either IKKa or IKKb by the upstream
kinases, including NFkB-inducing kinase (NIK) and
MEKK1 of the MAP3K family (16–19). The IkB is then
recruited into the IKK complex through phosphorylation of
serine residues. Although IKKa and IKKb share a high
degree of similarities in sequence and substrate specificity,
the analysis of IKK function by targeted disruption of the
corresponding genes in mice reveals that their functions are
not interchangeable. IKKa plays a crucial role in keratino-
cyte differentiation, but it is not required for cytokine-
dependent activation of NFkB. In contrast, IKKb is essen-
tial for NFkB activation by pro-inflammatory stimuli.
Recently, an additional IKK complex has been suggested
(20). This novel IKK complex contains an IkB kinase
referred as to IKK«. Intriguingly, the purified IKK« is
capable of phosphorylating only one of the serine residues,
S32, but not S36 of IkBa. However, the endogenous IKK«
derived from phorbol myristate acetate-treated cells could
phosphorylate both S32 and S36, implying the possibility of
another unknown IkB kinase existing in the IKK complex.
In addition, an LPS-inducible IkB kinase, IKKi, has also
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been identified (21). Expression of IKKi can be induced,
particularly in immune cells in response to LPS and pro-
inflammatory cytokines, including tumor necrosis factor-
alpha (TNF-a), interleukin (IL)-1b and IL-6. Overexpres-
sion of IKKi results in phosphorylation of IkBa,
preferentially S36. Moreover, IKKi has been shown to
phosphorylate TRAF1 as well as to induce c-Jun
N-terminal kinase upon stimulation (22). Thus, IKKi may
have more divergent functions than the other IKKs.
The kinase cascades for NFkB-activation may follow
several stimulus-dependent pathways. For example, protein
kinase C, protein kinase A, protein kinase R, Raf, eu-
karoytic initiation factor-2-kinase, casein kinase II and
mitogen-activated kinase can phosphorylate IkBa without
being site-specific (not on serine residues). Site-specific
kinases discussed above predominantly phosphorylate IKKb
(2–4). The composition of the NFkB dimer and its regu-
latory protein, the nature of the stimulus and the number of
concensus sites in the target gene will influence the activity
and amount of transcribed product after NFkB activation.
Additionally, NFkB works in cooperation with other tran-
scription factors, in particular, activator protein-1 (AP-1)
(1,23).
CELL BIOLOGICAL EFFECTS OF NFkB ACTIVATION
Pro-inflammatory cytokines produced by macrophages, T
cells and other cells exert their actions on target cells by
transactivating NFkB (i.e., by initiating the signal cascade
described above) (3,24,25). Most cells express receptors for
the pro-inflammatory cytokines, IL-1b and TNF-a, and
they also contain the IKK complex needed for signal
transduction. Cells such as leukocytes, vascular endothelial
and smooth muscle cells, cardiomyocytes and fibroblasts
therefore respond to pro-inflammatory cytokines by NFkB
activation (3,24–26). This leads to or enhances expression
of a host of genes, including those encoding several cyto-
kines (e.g., IL-6 and IL-12), leukocyte adhesion molecules
(e.g., ICAM-1, VCAM-1, E-selectin), matrix metallopro-
teinases, cyclooxygenase-2 and inducible nitric oxide (NO)
synthase (27–34). Also, NFkB activation induces the ex-
pression of pro-inflammatory cytokines in a positive feed-
back loop. By inducing secretion of IL-6, NFkB-mediated
stimuli act on the liver and brain to cause the systemic signs
of inflammation (35).
The NFkB pathway is used not only by pro-inflammatory
cytokines but also by microbial products. In particular,
endotoxins of gram-negative bacteria signal through NFkB
Abbreviations and Acronyms
IAP 5 inhibitor of apoptosis
ICAM 5 intercellular adhesion molecule
IL 5 interleukin
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Figure 1. A schematic presentation of activation of the transcription nuclear factor kappa-B (NFkB). In the cytoplasm of the resting cell, the NFkB dimer,
often consisting of the subunits p50/p65, is bound to inhibitory proteins known as inhibitory kappa-B (IkB). Stimuli activating IkB kinases will cause
nuclear translocation of the NFkB dimer, while IkB is proteolytically degraded. In the nucleus, NFkB binds to consensus sites in promoter/enhancer regions
of genes it regulates, and transcription of these substances commences. COX-2 5 cyclo-oxygenase-2 inhibitor; ICAM-2 5 intercellular adhesion molecule
2; IL 5 interleukin; iNOS 5 inducible nitric oxide synthase; LPS 5 lipopolysaccharide; MHC 5 major histocompatibility complex; TNF 5 tumor necrosis
factor; VCAM-1 5 vascular cell adhesion molecule-1.
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after ligation of their LPS moieties to receptors of the
Toll-like receptor (TLR) family (36,37). This gene family is
named after the Toll gene, a developmental regulatory gene
in Drosophila. Recently, TLR-4 was identified as the sig-
naling LPS receptor in man and other mammals (36,37).
Septic shock therefore causes symptoms indistinguishable
from those elicited when immune cells are activated to
produce pro-inflammatory cytokines (37). Both TLRs,
NFkB and downstream products such as NO, are phyloge-
netically old molecules, and it is likely that TLR/NFkB–
mediated response to bacteria has been a key mechanism
through evolution for the protection of multicellular organ-
isms against pathogenic invaders.
NFkB IN APOPTOSIS
Because the NFkB pathway is involved in pathological
responses, it was believed to activate cell-death pathways. In
endotoxinemia, acute and overwhelming NFkB activation
can indeed lead to widespread endothelial cell death with
permeability disturbances and disseminated coagulation
(26). However, it has become apparent that NFkB can also
protect cells from death. Tumor necrosis factor-alpha can
cause programmed cell death (i.e., apoptosis), and this is
often paralleled by increased NFkB activation (38). Surpris-
ingly, inhibition of NFkB increased rather than reduced cell
death in these experiments (39). This would suggest that
NFkB can actually serve as a survival factor. Such a
protective role for NFkB was also observed in p65/RelA
knockout mice, which died embryonally from extensive liver
apoptosis (40). A similar conclusion was reached in studies
of vascular smooth muscle cells, in which TNF-a can also
induce programmed cell death (41). These cells express
NFkB constitutively (42). If NFkB is inhibited (e.g., by the
chemical pyrrolidine dithiocarbamate or by transfecting a
virus that overexpresses IkBa), the smooth muscle cells die
(43,44).
The paradoxical “survival” action of NFkB is due to an
induction of antiapoptotic factors (40,45). In particular, the
genes for inhibitor of apoptosis protein-1 (IAP-1) (46) and
X-linked inhibitor of apoptosis protein (XIAP) contain
NFkB elements in its promoters (43,47). The NFkB
transactivation leads to IAP-1 and XIAP gene expression,
and the protein product inhibits several of the caspase
enzymes involved in the cell-death program. Additionally,
NFkB may upregulate the mitochondrial antiapoptotic
factor Bcl-2 (48), perhaps in a positive feedback loop as
Bcl-2 downregulates IkBa, thus increasing NFkB activa-
tion (49). Additional feedback loops modulate NFkB acti-
vation during cytokine signaling and the apoptotic cascade.
For instance, caspase 8 can inactivate the kinase RIP that is
needed for TNF-induced NFkB activation (50). Activation
of the caspase cascade during apoptosis therefore downregu-
lates NFkB-dependent antiapoptotic pathways.
Studies in different experimental models support the
notion that NFkB can protect cells from death. For in-
stance, loss of one of the NFkB subunits reduces cell death
in an ischemia/reperfusion stroke model (51). The
IKK 2/2 mice die at midgestation owing to massive liver
apoptosis, and IKK-deficient cells are sensitive to TNF-
induced apoptosis (52–54). Why can NFkB induce both
survival signals and detrimental molecules? A likely expla-
nation may be that the inflammatory program mediated
through NFkB activation generates toxic molecules that can
kill invading microorganisms without damaging the host
cells. The induction by NFkB of a survival program in
parallel with potentially dangerous enzymes such as matrix
metalloproteinase-9 and NO synthase (28,55,56) might
therefore provide protection for the cytokine-responding
cell. In addition, NFkB-mediated expression of iNOS will
eventually lead to an NO-dependent increase in IkBa
expression (57); this is likely to turn off the cytokine
program that involves signals for death as well as survival
and activation (58). It is apparent that the role of NFkB in
the regulation of cell viability is multidimensional and much
further work will be needed for a complete understanding of
these mechanisms.
NFkB IN MYOCARDIAL ISCHEMIA-REPERFUSION
Nuclear factor kappa-B is activated by myocardial ischemia
and reperfusion (59–61), including in the human heart
subjected to cardioplegia and reperfusion during open heart
surgery (62). In isolated hearts this starts shortly after
initiation of ischemia and is augmented by reperfusion (59).
In hearts subjected to in vivo infarction, NFkB-activation is
biphasic, peaking after 15 min and 3 h reperfusion, possibly
corresponding to a primary activation by reactive oxygen
intermediates and a secondary activation by pro-
inflammatory cytokines produced by the first activation
(60). A detrimental role of NFkB during reperfusion is
suggested indirectly by functional studies of the genes it
regulates: inhibition of leukocyte adhesion, cytokines, and
chemokines during reperfusion protects the heart against
reperfusion injury (61,63–65).
More direct evidence for a detrimental role of NFkB is
supplied by Morishita et al. (66), who transfected rats
intracoronary with a double-stranded oligonucleotide con-
taining the NFkB cis-element before coronary artery liga-
tion. The decoy inhibited NFkB activation during reperfu-
sion and concomitantly reduced infarct size (66). When the
decoy was used for transfection and heterotopic transplan-
tation three days prior to Langendorff-perfusion with
Krebs-Henseleit buffer containing rat leukocytes, improved
cardiac function during reperfusion was found together with
reduced neutrophil adherence and tissue IL-8 production
(67). Several of the genes that NFkB regulates, such as
cytokines and leukocyte adhesion molecules, are imple-
mented in reperfusion injury (61,63–65). Finally, a role of
NFkB-activation in cardiac allograft rejection has been
suggested, as pharmacological inhibition of NFkB prolongs
survival of heterotopic transplants (68).
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NFkB IN ISCHEMIC PRECONDITIONING
Ischemic preconditioning (short episodes of ischemia and
reperfusion), which profoundly reduces infarct size and
improves cardiac function during reperfusion, can be per-
formed less than 2 h (classic preconditioning) or 24 to 72 h
(delayed preconditioning) before sustained ischemia. How-
ever, the clinical application is thus far hampered by failure
to determine mechanisms underlying the response. A pos-
sible role for NFkB in ischemic preconditioning has recently
been suggested (69–71). Indirect evidence for this is pro-
vided by the intracellular signaling pathways of precondi-
tioning in rats and rabbits: activation of protein kinase C,
tyrosine kinase and p38 MAPK appears to be crucial for the
response, and these kinases also activate NFkB (69,70,72).
The NFkB is activated during the preconditioning episodes,
and pharmacological inhibition of NFkB abolishes the
cardioprotection in both classic and delayed models (69–
71). Trigger substances for preconditioning are suggested to
be reactive oxygen intermediates, which induce NFkB
activation (73). Adenosine has been indicated as another
trigger of the preconditioning response, as infusion of
adenosine can evoke the response, probably through A1
receptor stimulation. Purines may induce activation of
NFkB (74,75), although this finding is controversial (76).
Preconditioning of adenosine protected a human cardiomy-
ocyte cell line via a p38 MAPK pathway (77), whereas
adenosine A1 receptor stimulation could evoke delayed
preconditioning in the intact rabbit via upregulation of the
NFkB-regulated manganese superoxide dismutase (78). Ni-
tric oxide has been suggested as both a trigger and a
mediator of the preconditioning response, and this has
recently been reviewed by Bolli et al. (79). Nitric oxide
donors activate myocardial NFkB, and inhibition of NO
during the preconditioning episodes abolishes the beneficial
effects (79). The NO theory of preconditioning has recently
been linked to the adenosine theory, as A1 receptor agonists
could evoke preconditioning in wild-type mice but not in
mice with targeted disruption of the inducible NO synthase
gene (80).
Myocardial protection by NFkB activation may be caused
by induction of an NFkB-regulated mediator, such as
manganese superoxide disumutase as discussed above (78).
Recently, both inducible cyclooxygenase (81) and inducible
NO synthase (82) have been indicated as mediators of
delayed preconditioing through studies in knockout mice,
who, as opposed to the wild types, could not be protected by
preconditioning. Myocardial protection by NFkB activation
could also be caused by a downregulation of the inflamma-
tory response during reperfusion. Morgan et al. (71) found
a reduced activation of NFkB after sustained ischemia in
hearts that had been subjected to preconditioning. Similar-
ily, we found reduced activation of NFkB during ischemia
and reperfusion in hearts of rats that had been pretreated
with hyperoxia, probably secondary to an increase of IkBa
in hyperoxic hearts with induced protection (83). In human
umbilical vein endothelial cells preconditioned by hydrogen
peroxide, reduced upregulation of cytokines and leukocyte
adhesion molecules after subsequent stimulation with
TNF-a was found (84). Heat shock proteins of the 70-kDa
family, which are upregulated during preconditioning by
other pathways, have been suggested as mediators of isch-
emic adaption (85). Heat shock proteins modulate AP-1
and NFkB DNA binding activity (86,87) and might reduce
NFkB activation and thereby reduce inflammation during
reperfusion. A last possible route of NFkB-mediated car-
dioprotection is through the antiapoptotic effect of precon-
ditioning. Preconditioning reduces apoptosis during reper-
fusion, which may be linked to an NFkB-dependent
increase of cardiac Bcl-2 (48,70).
A ROLE FOR NFkB IN ATHEROSCLEROSIS
AND UNSTABLE CORONARY SYNDROMES
Nuclear factor kappa-B may play a role in the development
of atherosclerosis by transducing pathogenic stimulation to
expression of genes that promote recruitment and activation
of inflammatory cells in the plaque. The NFkB-regulated
inflammatory mediators such as cytokines, inducible NO
synthase and leukocyte adhesion molecules have been de-
tected in atherosclerotic lesions (88–90). Activated NFkB
has been indentified in macrophages, smooth muscle cells
and endothelial cells in human atherosclerotic plaques but
not in healthy vessels (91,92). Activation of NFkB may
occur after stimulation of lesional cells by pathogenically
important factors such as reactive oxygen species involved in
low-density lipoprotein oxidation and components of mi-
croorganisms such as Chlamydia pneumoniae (93). This
notion is supported by the observation that mice deficient in
NFkB signaling exhibit reduced fatty-streak formation
when fed a fatty diet (94).
Unstable coronary syndromes are currently believed to be
caused by rupture of an atherosclerotic plaque due to local
events, which may be of infectious, immunologic, or general
inflammatory etiology (95,96). Plaques from patients with
unstable coronary syndromes exhibit increased expression of
several NFkB-regulated genes, including tissue factor, an
initiator of coagulation, the cytokines IL-1, TNF-a,
interferon-g and IL-6 and inducible NO synthase
(89,91,95–100). These patients have a general inflammatory
response: the acute-phase reactant C-reactive protein is
increased, as are soluble leukocyte adhesion molecules and
markers of leukocyte activation (96,101–104). Ritchie (104)
recently showed that NFkB is activated in peripheral
leukocytes from patients with unstable angina. Interestingly,
it has lately been observed that pericardial fluid from
patients with unstable angina obtained during open heart
surgery induced apoptotic cell death in murine endothelial
cells independently of Fas and TNF-a (105). Apoptosis
may be important in plaque activation by destabilizing the
plaque cap (106). Whether the systemic response of unsta-
ble angina is a cause or a consequence of disease remains
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controversial. However, it is noteworthy that several pro-
teolytic enzymes proposed to be instrumental for plaque
rupture are transcriptionally regulated through NFkB ele-
ments.
Unstable angina reduces morbidity and mortality of acute
myocardial infarction, probably because of a precondition-
ing effect (107). We postulated that unstable angina would
elicit a tissue response analogous to cardiac and remote
preconditioning, and we assessed NFkB activation in right
atrial biopsies (108). Nuclear factor kappa-B was activated
in nuclear extracts from unstable patients with recent or
ongoing symptoms. Additionally, some of the protective
proteins associated with delayed preconditioning, namely
heat-shock protein 72 and endothelial NO synthase, were
increased in atrial tissue from unstable patients (108).
Paradoxically, unstable coronary syndromes increase the
morbidity and mortality of coronary artery bypass grafting
(109). It must be kept in mind in this context that unstable
patients scheduled for acute coronary revascularization are a
heterogenous group, where the time frame between onset of
symptoms and the surgery may be far beyond the range of
the time frame indicated for the preconditioning response (0
to 2 or 24 to 72 h).
Furthermore, open heart surgery represents a massive
inflammatory trauma with systemic increases of pro-
inflammatory cytokines, soluble leukocyte adhesion mole-
cules, neutrophil activation and endotoxemia due to major
surgery itself, extracorporeal circulation and cardiac isch-
emia-reperfusion (110). The inflammatory response to car-
dioplegia and reperfusion in patients with unstable angina is
more severe than in stable patients, evidenced as increased
myocardial gene expression of some NFkB-regulated me-
diators during reperfusion (62). Thus, the role of NFkB in
unstable coronary syndromes is not clear, and it appears to
be multifacilitated.
NFkB IN HEART FAILURE
Recent evidence has suggested that an inflammatory re-
sponse participates in the development of heart failure, and
NFkB may also be of importance in this aspect of pathol-
ogies (111–116). Myocardial tissue from patients with heart
failure of various etiologies exhibits activation of NFkB
(111) and increased expression of genes it regulates such as
inducible cyclo-oxygenase, TNF-a, inducible NO synthase
and leukocyte adhesion molecules (111–116). The expres-
sion of NFkB-regulated pro-inflammatory genes appears to
be independent of etiology of failure but appears connected
to the degree of disease (111–116). The human TLR-4 is
not expressed in the normal heart but is expressed in
remodeling murine myocardium and in patients with idio-
pathic dilated cardiomyopathy, indicating activation of in-
nate immunity in the injured myocardium (117). Signaling
to TLR-4 activation may be dependent on TLR-2 in
myocytes as a response to oxidative stress (118). When
either TLR-2 or TLR-4 was blocked, increased cytotoxicity
was found, indicating that NFkB is important for remod-
eling and repair of injured myocardium (117,118).
SUMMARY
Research over recent years indicates that the transcription
factor NFkB may play a key role in the pathophysiology of
myocardial ischemia-reperfusion injury, ischemic precondi-
tioning, apoptosis, atherosclerosis, unstable coronary syn-
dromes and heart failure. Although activation of NFkB
aggravates ischemic injury, it appears to trigger protection in
preconditioning. This may be due to reduction of apoptosis,
reduction of inflammation or upregulation of protective
substances such as manganese superoxide dismutase, induc-
ible cyclooxygenase and inducible NO synthase. Both sys-
temic and cardiac activation of NFkB have been found in
unstable coronary syndromes, although the functional con-
sequences are as yet undetermined. Thus, NFkB may be a
new therapeutic target for increased myocardial protection.
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